See more : Infineon Technologies AG (IFX.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Chinook Therapeutics, Inc. (KDNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chinook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Playfair Mining Ltd. (PLYFF) Income Statement Analysis – Financial Results
- Creative Realities, Inc. (CREX) Income Statement Analysis – Financial Results
- SillaJen, Inc. (215600.KQ) Income Statement Analysis – Financial Results
- Entheon Biomedical Corp. (ENBI.CN) Income Statement Analysis – Financial Results
- YourWay Cannabis Brands Inc. (YOUR.CN) Income Statement Analysis – Financial Results
Chinook Therapeutics, Inc. (KDNY)
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.13M | 51.63M | 827.00K | 17.26M | 15.09M | 17.24M | 50.68M | 72.98M |
| Cost of Revenue | 1.72M | 1.69M | 422.00K | 554.00K | 584.00K | 559.00K | 549.00K | 89.00K |
| Gross Profit | 4.41M | 49.94M | 405.00K | 16.70M | 14.50M | 16.68M | 50.13M | 72.89M |
| Gross Profit Ratio | 71.90% | 96.73% | 48.97% | 96.79% | 96.13% | 96.76% | 98.92% | 99.88% |
| Research & Development | 141.21M | 96.99M | 36.05M | 17.01M | 75.84M | 89.38M | 87.72M | 58.65M |
| General & Administrative | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Other Expenses | 1.72M | 1.69M | 422.00K | 299.00K | 3.99M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 115.86M | 123.13M | 122.00M | 86.45M |
| Cost & Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 116.45M | 123.69M | 122.54M | 86.54M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.18M | 0.00 | 15.00K | 33.00K | 0.00 | 0.00 | 2.22M | 494.00K |
| Depreciation & Amortization | 20.89M | 41.87M | 2.25M | 520.00K | 4.95M | 3.99M | 2.55M | 0.00 |
| EBITDA | -164.20M | -57.17M | -53.98M | -19.45M | -101.36M | -106.45M | -71.86M | -13.56M |
| EBITDA Ratio | -2,679.44% | -110.74% | -6,527.45% | -112.68% | -671.84% | -617.51% | -141.79% | -18.59% |
| Operating Income | -185.08M | -99.04M | -56.23M | -19.97M | -101.36M | -106.45M | -71.86M | -13.56M |
| Operating Income Ratio | -3,020.28% | -191.84% | -6,798.91% | -115.69% | -671.84% | -617.51% | -141.79% | -18.59% |
| Total Other Income/Expenses | 4.81M | -170.00K | -27.40M | -64.82M | 5.22M | 3.23M | 2.18M | -25.74M |
| Income Before Tax | -180.27M | -99.21M | -83.63M | -46.52M | -96.14M | -103.23M | -69.68M | -39.31M |
| Income Before Tax Ratio | -2,941.81% | -192.17% | -10,111.85% | -269.55% | -637.24% | -598.80% | -137.50% | -53.86% |
| Income Tax Expense | 4.34M | 2.09M | -2.00M | 332.00K | 783.00K | 11.36M | -21.46M | -99.00K |
| Net Income | -184.62M | -101.30M | -81.62M | -46.85M | -95.36M | -91.86M | -91.15M | -39.21M |
| Net Income Ratio | -3,012.65% | -196.22% | -9,869.65% | -271.47% | -632.05% | -532.88% | -179.85% | -53.73% |
| EPS | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
| Weighted Avg Shares Out (Dil) | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for...
CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chinook Therapeutics, Inc. (NasdaqGS: KDNY) to Novartis AG. Under the terms...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY
NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). Such investors are advised to contact Robert S.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for...
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY
NEW YORK , July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). Such investors are advised to contact Robert S.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for...
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ: KDNY)...
Source: https://incomestatements.info
Category: Stock Reports